Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -730.23% is 55% above its 4-year average of -1621.38%, around the middle of its 4-year range (-15141.28%–8172.22%).
28.42% above its 12-month average of -1020.18%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): -1089.25%.
NET PROFIT MARGIN
-730.23%
NET PROFIT MARGIN AVG TTM
-1020.18%
NET PROFIT MARGIN AVG 3Y
-1155.99%
NET PROFIT MARGIN AVG 5Y
N/A
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+28.42%
CURRENT VS 3Y AVG
+36.83%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.26%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-280757.69%
vs the sector median at left
60 Degrees Pharmaceuticals, Inc.
Market Cap
$3.83M
Net Profit Margin
-730.23%
TTM Avg
-1020.18%
3Y Avg
-1155.99%
5Y Avg
N/A
Market Cap
$3.98M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
64.44%
5Y Avg
-64.28%
Market Cap
$3.67M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$3.62M
Net Profit Margin
-694.19%
TTM Avg
-257.90%
3Y Avg
-726.73%
5Y Avg
-1357.15%
Market Cap
$3.63M
Net Profit Margin
0.00%
TTM Avg
-3826.38%
3Y Avg
-9879.36%
5Y Avg
-6586.24%
Market Cap
$4.11M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$3.64M
Net Profit Margin
-10.89%
TTM Avg
-10.89%
3Y Avg
-13.47%
5Y Avg
-4.61%
Market Cap
$3.49M
Net Profit Margin
-4139.38%
TTM Avg
-3617.24%
3Y Avg
-2890.13%
5Y Avg
-2863.43%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| 60 Degrees Pharmaceuticals, Inc. (SXTP) | $3.83M | -730.23% | -1020.18% | -1155.99% | N/A |
| Aptevo Therapeutics Inc. (APVO)vs › | $3.98M | 0.00% | 0.00% | 64.44% | -64.28% |
| Cadrenal Therapeutics, Inc. Common Stock (CVKD)vs › | $3.67M | 0.00% | 0.00% | 0.00% | 0.00% |
| Evogene Ltd. (EVGN)vs › | $3.62M | -694.19% | -257.90% | -726.73% | -1357.15% |
| Ernexa Therapeutics Inc. (ERNA)vs › | $3.63M | 0.00% | -3826.38% | -9879.36% | -6586.24% |
| Processa Pharmaceuticals, Inc. (PCSA)vs › | $4.11M | 0.00% | 0.00% | 0.00% | 0.00% |
| WORK Medical Technology Group Ltd. Class A (WOK)vs › | $3.64M | -10.89% | -10.89% | -13.47% | -4.61% |
| GRI Bio, Inc. (GRI)vs › | $4.22M | N/A | 0.00% | 0.00% | -421.83% |
| Nexalin Technology, Inc. (NXL)vs › | $3.49M | -4139.38% | -3617.24% | -2890.13% | -2863.43% |
| Eocene Ltd. (EOCN)vs › | $3.55M | N/A | N/A | N/A | N/A |
Operating Margin
-774.9%
Net Profit Margin
-730.2%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | -1089.25% |
| 2026-03-31 | -1289.49% |
| 2025-12-31 | -474.98% |
| 2025-09-30 | -529.48% |
| 2025-06-30 | -1717.72% |
| 2025-03-31 | -1147.37% |
| 2024-12-31 | -783.65% |
| 2024-09-30 | -1596.38% |
| 2024-06-30 | -3338.95% |
| 2024-03-31 | 407.36% |
| 2023-12-31 | -4584.98% |
| 2023-09-30 | 8172.22% |
| 2023-06-30 | -5604.64% |
| 2023-03-31 | -15141.28% |
| 2022-12-31 | 2214.14% |
| 2022-09-30 | -860.66% |
| 2022-06-30 | -4752.62% |
| 2022-03-31 | -1940.03% |
| 2021-12-31 | -474.81% |